BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18980540)

  • 41. Use of pneumococcal polysaccharide vaccine in children: what is the evidence?
    Borrow R; Heath PT; Siegrist CA
    Curr Opin Infect Dis; 2012 Jun; 25(3):292-303. PubMed ID: 22517603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 27th Annual Meeting of the European Society for Pediatric Infectious Disease.
    Dinleyici EC; Yargic ZA
    Expert Rev Vaccines; 2009 Sep; 8(9):1143-9. PubMed ID: 19722887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The potential cost-effectiveness of infant pneumococcal vaccines in Australia.
    Newall AT; Creighton P; Philp DJ; Wood JG; MacIntyre CR
    Vaccine; 2011 Oct; 29(45):8077-85. PubMed ID: 21864617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seven-valent pneumococcal conjugate vaccines for developing countries.
    Obaro S
    Expert Rev Vaccines; 2009 Aug; 8(8):1051-61. PubMed ID: 19627187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.
    Onwubiko C; Swiatlo E; McDaniel LS
    J Clin Microbiol; 2008 Nov; 46(11):3621-5. PubMed ID: 18845823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine.
    Aguiar SI; Serrano I; Pinto FR; Melo-Cristino J; Ramirez M;
    Clin Microbiol Infect; 2008 Sep; 14(9):835-43. PubMed ID: 18844684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
    Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
    Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of pneumococcal conjugate vaccines on otitis media-can we extrapolate to pneumonia?
    Dagan R
    Vaccine; 2008 Jun; 26 Suppl 2():B16-8. PubMed ID: 18793601
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?
    Musher DM; Sampath R; Rodriguez-Barradas MC
    Clin Infect Dis; 2011 Mar; 52(5):633-40. PubMed ID: 21292668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential.
    Hsieh YC; Lin PY; Chiu CH; Huang YC; Chang KY; Liao CH; Chiu NC; Chuang YC; Chen PY; Chang SC; Liu JW; Yen MY; Wang JH; Liu CY; Lin TY
    Vaccine; 2009 Sep; 27(40):5513-8. PubMed ID: 19615960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccines for other neonatal infections: pneumococcal disease: a major global health problem of young children.
    Richmond P
    Expert Rev Vaccines; 2004 Aug; 3(4):379-82. PubMed ID: 15270639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination.
    Barzilay EJ; O'Brien KL; Kwok YS; Hoekstra RM; Zell ER; Reid R; Santosham M; Whitney CG; Feikin DR
    Vaccine; 2006 Feb; 24(7):904-13. PubMed ID: 16203059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines.
    Talbird SE; Ismaila AS; Taylor TN
    Vaccine; 2010 Nov; 28 Suppl 6():G3-13. PubMed ID: 21075267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From global to regional: the importance of pneumococcal disease in Latin America.
    de Quadros CA
    Vaccine; 2009 Aug; 27 Suppl 3():C29-32. PubMed ID: 19540025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
    Ray GT
    Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination.
    Rozenbaum MH; Boersma C; Postma MJ; Hak E
    Expert Rev Vaccines; 2011 Feb; 10(2):187-99. PubMed ID: 21332268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serotype replacement in perspective.
    Dagan R
    Vaccine; 2009 Aug; 27 Suppl 3():C22-4. PubMed ID: 19545935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HHS-CDC news: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--US, 1998-2003.
    Ann Pharmacother; 2005 Nov; 39(11):1967-8. PubMed ID: 16219891
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.